A PROMISING COVID-19 TREATMENT GETS FAST-TRACKED
Arturo Casadevall and collaborators at Johns Hopkins and beyond have worked around the clock to develop a convalescent serum therapy to treat COVID-19 using blood plasma from recovered patients. If early promising studies on the therapy done in China are confirmed by U.S. trials, thousands of survivors might soon line up to donate their antibody-rich plasma. "I absolutely think this could be the best treatment we have for the next few months," Hopkins pathologist Aaron Tobian says.
"Mindboggling." That's how Aaron Tobian, a pathologist and director of the Division of Transfusion Medicine at Johns Hopkins Hospital, describes the speed of the spread of the COVID-19 virus—and Johns Hopkins' lightning-fast response to the pandemic. "When it started to hit the home front and there were no treatments, everybody started saying, 'We need to act, and we need to act now,'" says Tobian, who has a joint appointment in the Department of Epidemiology at the Bloomberg School of Public Health. "And that's when people at Hopkins started coming together and said, 'Let's try to do something here.'"